Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA | P06280 | 1/20 | 0.62 |
| ▸ | LTA4H | P09960 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9038558 | 0.82 | GLA (0.60) | GLALTA4HALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL9060376 | 0.81 | GLA (0.59) | GLALTA4HALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL25502064 | 0.79 | GLA (0.53) | GLAALDH1A1MAPK1L3MBTL1HTR2C | |
| SCHEMBL17726560 | 0.78 | HTR2C (0.55) | GLAALDH1A1MAPK1L3MBTL1HTR2C | |
| SCHEMBL22404739 | 0.78 | MAN2A1 (0.43) | GLALTA4HALDH1A1MAPK1L3MBTL1 | |
| Hydrochloric Acid SCHEMBL25205278 | 0.78 | GLA (0.52) | GLAALDH1A1MAPK1L3MBTL1HTR2C | |
| SCHEMBL29036584 | 0.78 | GLA (0.55) | GLAALDH1A1MAPK1L3MBTL1HTR2C | |
| SCHEMBL27372387 | 0.77 | TSHR (0.54) | GLAALDH1A1MAPK1L3MBTL1HTR2C | |
| SCHEMBL28008564 | 0.77 | ALDH1A1 (0.52) | GLALTA4HALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL8948696 | 0.77 | KMT2A (0.51) | GLAALDH1A1MAPK1L3MBTL1HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100249411-A1 | Stereoselective Alkylation of Chiral 2-Methly-4 Protected Piperazines | WU WENXUE | 2010-09-30 | — | — | US | disclosed |
| US-7745626-B2 | Stereoselective alkylation of chiral 2-methyl-4-protected piperazines | SCHERING CORPORATION (US) | 2010-06-29 | — | — | US | disclosed |
| EP-2141143-A2 | Stereoselective alkylation of chiral 2-methyl-4 protected piperazines | SCHERING CORPORATION (US) | 2010-01-06 | — | — | EP | disclosed |
| EP-2141153-A2 | Stereoselective alkylation of chiral 2-methyl-4 protected piperazines | SCHERING CORPORATION (US) | 2010-01-06 | — | — | EP | disclosed |
| EP-1490346-B1 | STEREOSELECTIVE ALKYLATION OF CHIRAL 2-METHYL-4-PROTECTED PIPERAZINES | SCHERING CORP (US) | 2009-12-02 | — | — | EP | disclosed |
| US-20050171120-A1 | Stereoselective alkylation of chiral 2-methyl-4-protected piperazines | WU WENXUE (US) | 2005-08-04 | — | — | US | disclosed |
| US-6872826-B2 | Stereoselective alkylation of chiral 2-methyl-4-protected piperazines | SCHERING CORPORATION (US) | 2005-03-29 | — | — | US | disclosed |
| EP-1490346-A2 | STEREOSELECTIVE ALKYLATION OF CHIRAL 2-METHYL-4-PROTECTED PIPERAZINES | SCHERING CORPORATION (US) | 2004-12-29 | — | — | EP | disclosed |
| US-20030208074-A1 | Stereoselective alkylation of chiral 2-methyl-4-protected piperazines | SCHERING CORPORATION | 2003-11-06 | — | — | US | disclosed |
| WO-2003084942-A2 | STEREOSELECTIVE ALKYLATION OF CHIRAL 2-METHYL-4-PROTECTED PIPERAZINES | SCHERING CORPORATION (US) | 2003-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171120-A1 | Stereoselective alkylation of chiral 2-methyl-4-protected piperazines | AZI2, ALKBH5, DNMT1 | GLA 4604/4885LTA4H 2577/4885ALDH1A1 578/4885 |
| US-20030208074-A1 | Stereoselective alkylation of chiral 2-methyl-4-protected piperazines | AZI2, DNMT1, ALKBH5 | GLA 4619/4885LTA4H 2653/4885ALDH1A1 492/4885 |
| US-20100249411-A1 | Stereoselective Alkylation of Chiral 2-Methly-4 Protected Piperazines | ALKBH5, AZI2, PNMT | GLA 4793/4885LTA4H 2154/4885ALDH1A1 449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.